Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASKB1202
- Development stage
- Phase 1
- Lead developer
- Jiangsu Aosaikang Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ASKB1202 is a biosimilar to bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with receptors. By targeting VEGF, it inhibits angiogenesis (formation of new blood vessels), which is crucial for tumor growth and metastasis. The drug was developed by Jiangsu Aosaikang Pharmaceutical Co. Ltd.
02
Targets
Beyond the preview
Go deeper on ASKB1202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASKB1202.